Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Claims 1-19 (canceled)

Claim 20 (Previously Presented) A hydrophilic controlled release solid formulation comprising 9-hydroxyrisperidone, a pharmaceutically acceptable acid addition salt thereof, an N-oxide form thereof, or a stereochemically isomeric form thereof ~~in a subject~~, and one or more viscous hydrophilic polymers.

Claim 21 (Previously Presented) The controlled release formulation of claim 20, wherein said one or more hydrophilic polymers are selected from the group consisting of alkylcellulose, hydroxyalkylcellulose, hydroxyalkylalkylcellulose, carboxyalkylcellulose, alkali metal salts of carboxyalkylcellulose, natural, semi-synthetic or synthetic polysaccharide, polyacrylic acid and salts thereof, polymethacrylic acid and the salts thereof, polyvinyl alcohol, polyvinylpyrrolidone, and polyalkylene oxides.

Claim 22 (Previously Presented) The controlled release formulation of claim 20, wherein said one or more hydrophilic polymers are selected from the group consisting of hydroxypropyl cellulose and hydroxypropylmethylcellulose.

Claim 23 (Previously Presented) The controlled release formulation of claim 22, wherein said hydroxypropylmethylcellulose has a viscosity in a range from about 3,500 mPa.s to about 100,000 mPa.s.

Claim 24 (Previously Presented) The controlled release formulation of claim 22, wherein said hydroxypropylcellulose has a viscosity of less than about 1,500 mPa.s.

Claim 25 (Previously Presented) The controlled release formulation of claim 20, wherein said one or more hydrophilic polymers are present in an amount from about 0.01 to about 80 % by weight.

Claim 26 (Previously Presented) The controlled release formulation of claim 20, wherein at least two hydrophilic polymers are present in said formulation.

Claim 27 (Previously Presented) The controlled release formulation of claim 26, wherein said at least two hydrophilic polymers are hydroxypropylcellulose and hydroxypropylmethylcellulose.

Claim 28 (Previously Presented) The controlled release formulation of claim 27, wherein a ratio of said hydroxypropylcellulose to said hydroxypropylmethylcellulose ranges from 1:5 to 5:1.

Claim 29 (Previously Presented) The controlled release formulation of claim 20, further comprising pregelatinized starch.

Claim 30 (Previously Presented) The controlled release formulation of claim 29, wherein said pregelatinized starch is present at about 0.01 – 15 % by weight.

Claim 31 (Previously Presented) The controlled release formulation of claim 20 further comprising cyclodextrin or a derivative thereof.

Claim 32 (Previously Presented) A method of providing controlled release of 9-hydroxyrisperidone, a pharmaceutically acceptable acid addition salt thereof, an N-oxide form thereof, or a stereochemically isomeric form thereof in a subject, comprising administering the controlled release formulation of claim 20 to said subject.

Claim 33 (Previously Presented) A method of preparing a controlled release formulation comprising a step of mixing hydroxyrisperidone, a pharmaceutically acceptable acid addition salt thereof, an N-oxide form thereof, or a stereochemically isomeric form thereof, with one or more hydrophilic polymers.

Claim 34 (Previously Presented) A controlled release formulation comprising 9-hydroxyrisperidone, a pharmaceutically acceptable acid addition salt thereof, an N-oxide form thereof, or a stereochemically isomeric form thereof, and one or more hydrophilic polymers in a dosage form.